Intelligence · Clinical Development
Pipeline search results
Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Placebo matching to spesolimab
Boehringer Ingelheim
Pyoderma gangrenosum
1 trial -
Placebo of BELAPECTIN, BELAPECTIN
GALECTIN THERAPEUTICS INC
Esophageal Varices in NASH Cirrhosis
1 trial -
Placebo of Zodasiran, ARO-ANG3
Arrowhead Pharmaceuticals Ireland Limited
Homozygous Familial Hypercholesterolemia (HoFH)
1 trial -
Placebo to Descartes-08, Descartes-08
Cartesian Therapeutics
generalized myasthenia gravis
1 trial -
Placebo to MK-7240 (Tulisokibart), tulisokibart
Merck Sharp and Dohme
Crohn’s Disease or Ulcerative Colitis
1 trial -
Placebo to Povorcitinib, Povorcitinib
Incyte
Vitiligo
1 trial -
Placebo to Upadacitinib
AbbVie
Rheumatoid Arthritis
1 trial -
Placebo to match 10 mg, Placebo to match 5 mg
Gilead Sciences Pty Limited
Primary Biliary Cholangitis
1 trial -
Placebo to match LY
Eli Lilly Co.
Overweight or Obesity, OSA (Obstructive Sleep Apnea)
1 trial -
Placebo to match LY, Muvalaplin
Eli Lilly Co.
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
1 trial -
Placebo, CEMIPLIMAB
Ningbo Cancer Hospital
Non-small cell lung cancer
1 trial -
Placebo, Etavopivat A 200 mg
NovoThirteen
Sickle cell disease
1 trial -
Placebo, Velcade and dexamethasone
Centocor B.V.
Multiple Myeloma
1 trial -
Placebo, XPF-010
Xenon Pharmaceuticals
Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)
1 trial -
Placebos
Jian Li
Advanced Non-small Cell Lung Cancer
1 trial -
Plozasiran Injection Placebo, ARO-APOC3 PFS
Arrowhead Pharmaceuticals Ireland Limited
Severe hypertriglyceridemia (SHTG)
1 trial -
Plozasiran Injection Placebo, ARO-APOC3 PFS
Arrowhead Pharmaceuticals Ireland Limited
Severe hypertriglyceridemia (SHTG)
1 trial -
Povorcitinib, Placebo to Povorcitinib
Incyte
Vitiligo
1 trial -
RO7046015, Placebo Prasinezumab
Hoffmann-La Roche
Early-Stage Parkinson’s Disease (PD)
1 trial -
RO7790121 Placebo, RO7790121
Hoffmann-La Roche
Moderately to Severely Active Crohn's Disease (CD)
1 trial -
RO7790121, RO7790121 Placebo
Hoffmann-La Roche
Moderately to Severely Active Ulcerative Colitis (UC)
1 trial -
RO7790121, RO7790121 Placebo
Hoffmann-La Roche
Moderately to Severely Active Crohn's Disease (CD)
1 trial -
Ramelteon and Placebo (9 possible combinations total)
Takeda
Chronic Insomnia
1 trial -
Remternetug, Placebo to match LY
Eli Lilly Co.
Alzheimer’s Disease
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.